Literature DB >> 31323221

Soluble angiotensin converting enzyme 2 levels in chronic heart failure is associated with decreased exercise capacity and increased oxidative stress-mediated endothelial dysfunction.

Zhili Shao1, Andres Schuster2, Allen G Borowski3, Akanksha Thakur4, Lin Li1, Wai Hong Wilson Tang5.   

Abstract

The aim of this study was to explore the relationship between serum soluble angiotensin converting enzyme 2 (sACE2), parameters of cardiopulmonary exercise testing and plasma asymmetric dimethylarginine (ADMA), a marker of oxidative stress-induced endothelial dysfunction. This has not been previously evaluated. We assessed 50 consecutive ambulatory patients with chronic systolic heart failure and left ventricular ejection fraction (LVEF) ≤45%. Their blood samples were collected for sACE2 and ADMA tests before they underwent symptom-limited cardiopulmonary exercise testing and transthoracic echocardiography. The majority of our study subjects had New York Heart Association functional class II (74%) and III (18%) presentation, and 42% of patients had ischemic etiology. Median sACE2 activity was 10.36 (7.00-14.47) ng/mL and mean ADMA was 0.90 ± 0.22. sACE2 activity was inversely correlated with pVO2 (r = -0.42, P = 0.00283), exercise time (r = -0.35, P = 0.0138) and LVEF (r = -0.548, P < 0.001), and positively correlated with VE/VCO2 slope (r = 0.294, P = 0.0405), ΔDBP (r = 0.315, P = 0.0278), mitral E/Ea ratio (r = 0.442, P = 0.00158) and ADMA levels (r = 0.351, P = 0.0134). Meanwhile, we observed a negative correlation between ADMA and pVO2 (r = -0.424, P = 0.00227) and positive correlations between ADMA and VE/VCO2 slope (r = 0.515, P < 0.001), ΔDBP (r = 0.391, P = 0.00568), mitral E/Ea ratio (r = 0.426, P = 0.00219). In multivariate logistic regression analysis, sACE2 was independently associated with peak oxygen uptake (% predicted) after adjusting for body mass index (BMI) and mitral E/Ea ratio (odds ratio [OR] 0.81 (0.58-0.94), P = 0.041) and associated with oxygen pulse (VO2/HR) (%) after adjusting for age, gender, BMI and mitral E/Ea ratio (OR 0.83 [0.68-0.95], P = 0.025). Therefore in stable chronic systolic heart failure patients, higher sACE2 activity is independently associated with diminished exercise capacity and correlates with elevated systemic oxidative stress-mediated endothelial dysfunction.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31323221      PMCID: PMC6755052          DOI: 10.1016/j.trsl.2019.06.004

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  30 in total

1.  Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.

Authors:  Matthew J Huentelman; Justin L Grobe; Jorge Vazquez; Jillian M Stewart; Adam P Mecca; Michael J Katovich; Carlos M Ferrario; Mohan K Raizada
Journal:  Exp Physiol       Date:  2005-07-27       Impact factor: 2.969

2.  Determinants of functional capacity in patients with chronic heart failure: role of filling pressure and systolic and diastolic function.

Authors:  Neil Smart; Brian Haluska; Rodel Leano; Colin Case; Philip M Mottram; Thomas H Marwick
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

3.  G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor.

Authors:  Evi Kostenis; Graeme Milligan; Arthur Christopoulos; Carlos F Sanchez-Ferrer; Silvia Heringer-Walther; Patrick M Sexton; Florian Gembardt; Elaine Kellett; Lene Martini; Patrick Vanderheyden; Heinz-Peter Schultheiss; Thomas Walther
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

4.  Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure.

Authors:  Montserrat Batlle; Eulàlia Roig; Fèlix Perez-Villa; Sergio Lario; Pilar Cejudo-Martin; Ester García-Pras; José Ortiz; Mercé Roqué; Josefina Orús; Montserrat Rigol; Magdalena Heras; José Ramírez; Wladimiro Jimenez
Journal:  J Heart Lung Transplant       Date:  2006-08-09       Impact factor: 10.247

5.  Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats.

Authors:  Annemarieke E Loot; Anton J M Roks; Robert H Henning; René A Tio; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

6.  Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.

Authors:  Paul W M Fedak; Christine S Moravec; Patrick M McCarthy; Svetlana M Altamentova; Amy P Wong; Marko Skrtic; Subodh Verma; Richard D Weisel; Ren-Ke Li
Journal:  Circulation       Date:  2006-01-09       Impact factor: 29.690

7.  A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.

Authors:  M Donoghue; F Hsieh; E Baronas; K Godbout; M Gosselin; N Stagliano; M Donovan; B Woolf; K Robison; R Jeyaseelan; R E Breitbart; S Acton
Journal:  Circ Res       Date:  2000-09-01       Impact factor: 17.367

8.  Angiotensin-converting enzyme 2 is an essential regulator of heart function.

Authors:  Michael A Crackower; Renu Sarao; Gavin Y Oudit; Chana Yagil; Ivona Kozieradzki; Sam E Scanga; Antonio J Oliveira-dos-Santos; Joan da Costa; Liyong Zhang; York Pei; James Scholey; Carlos M Ferrario; Armen S Manoukian; Mark C Chappell; Peter H Backx; Yoram Yagil; Josef M Penninger
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

9.  Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins.

Authors:  Mary Donoghue; Hiroko Wakimoto; Colin T Maguire; Susan Acton; Paul Hales; Nancy Stagliano; Victoria Fairchild-Huntress; Jian Xu; John N Lorenz; Vivek Kadambi; Charles I Berul; Roger E Breitbart
Journal:  J Mol Cell Cardiol       Date:  2003-09       Impact factor: 5.000

10.  Relation of the prognostic value of ventilatory efficiency to body mass index in patients with heart failure.

Authors:  Paul Chase; Ross Arena; Jonathan Myers; Joshua Abella; Mary Ann Peberdy; Marco Guazzi; Daniel Bensimhon
Journal:  Am J Cardiol       Date:  2007-12-21       Impact factor: 2.778

View more
  6 in total

1.  Temporal changes in soluble angiotensin-converting enzyme 2 associated with metabolic health, body composition, and proteome dynamics during a weight loss diet intervention: a randomized trial with implications for the COVID-19 pandemic.

Authors:  Nicholas Cauwenberghs; Mary Prunicki; František Sabovčik; Dalia Perelman; Kévin Contrepois; Xiao Li; Michael P Snyder; Kari C Nadeau; Tatiana Kuznetsova; Francois Haddad; Christopher D Gardner
Journal:  Am J Clin Nutr       Date:  2021-11-08       Impact factor: 8.472

2.  Qishen Yiqi dropping pills improve isoproterenol-induced cardiomyocyte hypertrophy by regulating X-inactive specific transcript (XIST) expression in rats.

Authors:  Ying Luo; Jiaxian Chen; Yuewu Chen; Yangshen Su; Xiaoyan Wu; Wanling Zheng; Xianxia Liu; Lei Chen
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

Review 3.  The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19.

Authors:  Artemio García-Escobar; Santiago Jiménez-Valero; Guillermo Galeote; Alfonso Jurado-Román; Julio García-Rodríguez; Raúl Moreno
Journal:  Heart Fail Rev       Date:  2021-01-06       Impact factor: 4.214

Review 4.  ACE2 Shedding and the Role in COVID-19.

Authors:  Jieqiong Wang; Huiying Zhao; Youzhong An
Journal:  Front Cell Infect Microbiol       Date:  2022-01-14       Impact factor: 5.293

Review 5.  Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.

Authors:  Tomas Rajtik; Peter Galis; Linda Bartosova; Ludovit Paulis; Eva Goncalvesova; Jan Klimas
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

Review 6.  Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19.

Authors:  Artemio García-Escobar; Silvio Vera-Vera; Alfonso Jurado-Román; Santiago Jiménez-Valero; Guillermo Galeote; Raúl Moreno
Journal:  Biomolecules       Date:  2022-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.